Tag: therapies

Boca Raton, FL, July 23, 2025 (GLOBE NEWSWIRE) -- Hydrasphere Plus, a Florida-based skincare innovator, has officially launched a pioneering three-pillar system designed to transform the science of facial health. Built on decades of dermatological research and cosmetic formulation expertise, the new Hydrasphere Plus system uniquely targets skin texture, facial muscle tone, and collagen production—three biological pillars essential to long-term skin vitality.

Collaboration includes strategic investment by CharacterStrong’s parent company FullBloom to further scale K-12 mental health solutions that improve student outcomes

- XIPERE Now Approved for Use in Multiple Global Markets -

Hennigsdorf/ Berlin, July 23, 2025 – 4TEEN4 Pharmaceuticals GmbH today announced that the first patient has been dosed in a Phase 1b/2a PROCARD1 clinical trial evaluating its monoclonal antibody, procizumab, in patients with shock caused primarily by cardiogenic events. Shock is a life-threatening condition characterized by a sudden breakdown in circulatory function due to end-stage disease or acute events, which often leads to organ failure. With only symptomatic treatment options available, shock is associated with a high mortality rate of over 50%. The Phase 1b/2a trial is designed to identify a target dose for procizumab in preparation for further clinical development. In addition, the trial will provide signals of efficacy. In a Phase 1 study in healthy volunteers, procizumab was well tolerated.

Compounds developed through collaboration with Variational AI show targeted activity

PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:

Not For Distribution to United States News Wire Services or for Dissemination in the United States